Interleukin-23 receptor

Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis

This phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.